Targeting EGFR in Glioblastoma

Targeting EGFR in Glioblastoma

Where We’ve Been and Where We’re Going

Not a member of My prIME? Join now for instant access.

The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Industry Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.

Meeting Overview

Explore the options for EGFR-targeted therapy in the treatment of patients with glioblastoma (GBM). This live satellite symposium provides a focused look at EGFR in GBM, including a discussion of the role and timing of biomarker testing, as well as a review of EGFR-targeted therapies currently under investigation in GBM. Don’t miss out the most up-to-date information from expert investigators.

Date and location

Saturday, November 18, 2017
12.15 PM – 1.15 PM

Yerba Buena 13-15
San Francisco Marriott Marquis
780 Mission Street
San Francisco, California 94103



Saturday, November 18, 2017
12.15 PM – 1.15 PM



San Francisco, California, United States



1.0 AMA PRA Category 1 Credit

Welcome and introduction
David Reardon, MD
12.15 PM Quiz questions
David Reardon, MD
12.20 PM Molecular classification and the search for targets in GBM
John H. Sampson, MD, PhD
12.35 PM Questions from the audience
12.40 PM Drilling down on EGFR-targeted therapy
Andrew Lassman, MD
1.00 PM Faculty panel discussion and questions from the audience
All Faculty
1.10 PM prIME Points™
David Reardon, MD
1.15 PM Adjourn


  • David Reardon, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Faculty

  • Andrew Lassman, MDColumbia University
    New York, New York, United States
  • John H. Sampson, MD, PhD Duke University
    Durham, North Carolina, United States

This live activity is designed to meet the needs of the attendees of the SNO Annual Meeting, as well as medical oncologists, neuro-oncologists, and other healthcare professionals involved in the treatment of patients with GBM.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the molecular subgroups that are being incorporated into classification of GBMs
  • Assess EGFR testing in GBM and the role of repeat biopsy at the time of progressive disease
  • Summarize the different EGFR-targeted strategies being investigated in GBMs

This educational activity is supported by a grant from AbbVie.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


prIME Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.